License
One country. One licensee.
Jowin is selecting one exclusive partner per country to localize the HealthInsu™ model. Patents, formulas, ingredient supply, insurance-linked structure, sales know-how, and brand — all included under a single master agreement.
What's included
Six asset layers, one master agreement.
Patents
Layered business-model and system patents covering the HealthInsu™ structure in your jurisdiction.
Disease-specific recipes
Validated preventive-health formulations developed over more than a decade of R&D.
Key ingredient supply chain
Access to core ingredients and supplier relationships needed to manufacture under quality controls.
Insurance-linked design
The structural design of how subscription, examination, and insurance benefit interlock.
Sales & trial know-how
Trial-program model, customer-acquisition logic, sub-licensing structures, and partner enablement.
HealthInsu™ brand usage
Rights to use the HealthInsu™ and Jowin brand assets within your country, under brand standards.
Country-level economics
Indicative budget for launching one country.
Actual terms are agreed under separate contract and adjusted to market.
Country-level exclusivity, IP, structural license.
Local entity, team, and operating infrastructure.
Trial-program recruitment, video distribution, partner outreach.
Total indicative ≈ USD 3,000,000 per country
Country-level independent rights, sub-licensing terms, and long-term revenue structure are agreed under separate license agreement.
Self-funded structures
Partners without full upfront capital can still launch.
Structure local insurers, manufacturers, and marketing companies as investors who are also future business stakeholders.
Future product partner
Invests as a future insurance-product partner for the HealthInsu™ structure in the country.
Long-term manufacturing
Invests as a long-term manufacturer and supplier — secures recurring volume.
Exclusive marketing rights
Invests in exchange for exclusive local marketing rights and long-term ad spend.
A structured trial program (subsidized clinical trial recruitment) can additionally generate working capital ahead of the full launch — a model already used in Korea.
Licensee revenue model
Five revenue layers, not just product sales.
Subscription revenue
Recurring revenue from disease-specific prevention product subscriptions.
Insurance commissions
Commissions and structuring fees from local insurer partnerships tied to the HealthInsu™ benefit.
B2B partnership fees
Co-marketing or distribution fees from local supplement manufacturers, clinics, and corporate-wellness programs.
Sub-licensing
Vertical sub-licenses to local disease-specific operators under your country-level master license.
Data-product revenue
Aggregated, de-identified usage and outcome reports — sold to local insurers, manufacturers, and policy bodies.
Revenue mix
For most markets, recurring subscription and insurance commissions are the largest two layers, but the mix shifts based on local insurance maturity and channel partners.
90-day country feasibility
Both sides qualify the country together — before either side signs.
-
Days 1–14 · Briefing
NDA & structure briefing
NDA signed. Jowin walks through the full HealthInsu™ structure, patent scope, and reference data with your team.
-
Days 15–45 · Scan
Local regulatory & insurance scan
Joint review of local health-supplement regulation, insurance product framework, advertising rules, and data-protection requirements.
-
Days 46–75 · Network
Partner shortlist
Identify 2–3 candidate local insurers, 2–3 candidate manufacturers, and at least one clinical or hospital partner per disease vertical.
-
Days 76–90 · Terms
Country term sheet
Localized license term sheet — exclusivity scope, sub-licensing rights, milestone targets, marketing obligations, and pilot design.
-
From Day 90 · Pilot
Pilot launch
100-person pilot per the agreed design. 12-month observation window before full launch.
-
From Month 12 · License
Full master license
Pilot results inform the long-form master license — terms, royalties, milestones, and sub-licensing scope.
The 90-day feasibility window is a no-commitment period — it confirms HealthInsu™ can be localized in your country before either side signs a long-form license.
Market priority
Start small. Localize fast. Expand by track.
We prioritize markets where local insurers, manufacturers, and clinical partners can be connected quickly — not necessarily the largest TAM first.
Fastest partner velocity
Insurers, distributors, and supplement manufacturers in SEA tend to move quickly on prevention-linked structures. Strong candidates for first-wave country licenses.
Cross-border trust
Existing Korea–Japan cross-market understanding and community-based trust shorten the partner-introduction loop. Japanese-language materials prepared.
Different structures, same model
Markets with different insurance frameworks where the HealthInsu™ structure still maps — particularly via supplement + private-insurance combinations.
Korean reference structure
Already active in Korea, across six disease verticals.
Jowin licenses its prevention patents to disease-specific Korean partners and runs vertical HiClinic specialty companies with physicians. This is the reference structure the global licensing is modeled on.
Glucose-management prevention
Diabetes-prevention products linked to physician check-ups and risk-management programs.
Cancer-prevention category
Disease-specific prevention products with structured validation. Launched and sold out.
Cervical & women's cancer
Distributed through obstetrics & gynecology networks.
Eye-health subscription
Eye-health supplements + ophthalmology examinations + lifetime presbyopia-glasses benefit tied to continued subscription.
Gum & tooth health
Dentist-validated preventive products with check-up integration.
Orthopedic & joint
Joint-health prevention designed with orthopedic specialists.
Ready?
Tell us your country, your network, and your interest.
We respond within a few business days. Strong fits are invited to a Zoom meeting to discuss country exclusivity, structure, and timing.